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the STOP-NIDDM trial was developed to replicate the manage-
ment of IGT patients over the 3.3-year trial period. The cost-
effectiveness measures were cost per patient free of diabetes and
cost per month free of diabetes. Analyses were performed for the
total trial population and three subgroups: high risk for diabetes,
high risk for CV disease and high risk for combined diabetes-CV
disease. Total direct costs were calculated using standard sources
and published literature. Costs and outcomes were discounted 
at 3% and extensive sensitivity analyses were conducted.
RESULTS: The incremental cost per patient free of diabetes
(month free of diabetes) was 3032€ (136€) and 829€ (35€) 
for the total study population and high risk diabetes sub-
group respectively. Acarbose treatment dominated (i.e. was 
more effective, less costly) placebo in subgroups at high CV 
risk and high combined diabetes-CV risk. Deterministic sensi-
tivity analyses showed that the discount rate for costs and the
probability of transition to diabetes had the largest impact on
results. CONCLUSIONS: Acarbose treatment signiﬁcantly
reduces the incidence of diabetes and CV events in IGT patients.
This clinical advantage is expected to lead to reductions in
healthcare costs that exceed the acquisition cost of acarbose, thus
resulting in overall cost savings in high risk subgroups for CV
disease and combined diabetes-CV disease. For the total study
population and the high risk diabetes subgroup, savings from
fewer cases of diabetes and CV events partly offset the cost of
acarbose.
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OBJECTIVE: To estimate the cost of intensive treatment of DM
T2patients (insulin therapy and combined treatment with insulin
and oral hypoglycemic agents (OHAs)). METHODS: The study
was conducted for 24 weeks and included 4 visits. In total, 153
patients in DM T2 were examined (65% women and 35% men).
The average age was 56.7 years, the duration of the disease was
9.5 years. The cost of treatment included: the cost of patient
observation, daily test monitoring, diagnostic manipulations and
consultations and cost of the medicines used. Analysis of expen-
ditures was conducted using the incremental cost estimation
method that takes into account only the changing quantities.
RESULTS: All the patients were divided into two groups in
dependence on the result obtained: group 1 (85pts.), with a level
of HbA1c < or = 7.0%, and group 2 (68pts.), with a level of
HbA1c > 7% (p = 0.2784). In group 1, 60 patients received
insulin monotherapy and 25—a combination of insulins and
OHAs. In group 2, these subgroups counted 34 and 34 patients,
respectively. The intensive treatment was associated with
increases in the patient management costs by USD 0.89/patient
in group 1 and USD 0.78/patient group 2. The cost of treatment
increased because of an increase in the consumption of insulin
and expenditures on intensive observation. CONCLUSION:
The cost of achieving the clinical efﬁcacy criteria in the group
where optimal glycemic control was achieved turned out to be
comparable with the cost of managing patients in the group
where this control was not achieved. However, in group 1, a
decrease in the cost of treatment of concurrent diseases was
noted. Thus, proof was obtained: glycemic control is the major
determinant of the development of cardiovascular complications
of advanced DM.
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OBJECTIVES: Various delivery systems for inhaled insulin (INI)
are under development. However, they will likely be substantially
more expensive than subcutaneous insulin (SCI). Whether this
increased cost is justiﬁed is an important question which can be
addressed through Contingent Valuation (CV), a survey tech-
nique that elicits individuals’ preferences for non-marketed prod-
ucts in terms of the amount they would be willing-to-pay. The
purpose of this study was to assess diabetic (DM) patients’ pref-
erence and willingness-to-pay (WTP) for INI. METHODS: A
face-to-face CV survey was administered to 96 type-1 and type-
2 adult DM patients at St. Michael’s Hospital (Toronto, Canada)
who were taking insulin and/or oral antihyperglycaemic drugs.
Standardized information about INI and SCI was provided by
video, and participant’s WTP was elicited using “payment scale”
method, along with socioeconomic and clinical data. Published
data was used to deﬁne INI attributes. The CV questionnaire
received expert review for content validity and was pilot tested
with 22 patients. RESULTS: Participants were 51.8 ± 13.4 years
old, and had DM for an average of 11.8 ± 7.8 years; 77 had
type-2 and 19 had type-1 DM. Signiﬁcantly more participants
(89%) preferred INI over SCI (P < 0.01). The mean monthly
WTP for INI ($153.70 ± $99.90) was signiﬁcantly more than
typical SCI cost of $50 (P < 0.01). A greater proportion of type-
2 patients (n = 72/77) preferred INI than did type-1 patients 
(P < 0.001). The mean WTP for INI in type-2 subgroup ($177.10
± $91.60) was signiﬁcantly more compared to type-1 ($154 ±
$66.6, P = 0.025). Signiﬁcantly more participants who were not
on insulin preferred INI compared to participants using insulin
(P < 0.001). Multiple-regression analysis showed strong associ-
ation between participants’ income and insulin experience and
their WTP for INI (P < 0.001). CONCLUSIONS: DM patients
prefer INI over SCI and are willing-to-pay signiﬁcantly more per
month than the cost of SCI. Preferences are stronger in type-1
patients DM and those with prior insulin experience.
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OBJECTIVES: Type-2 diabetes mellitus is a chronic and pro-
gressive disease with a negative impact on quality of life. Objec-
tives of the present study were to describe Health-Related
Quality of life (HRQOL) in type-2 diabetes mellitus and to
compare the health state between diabetic and non-diabetic sub-
jects. METHODS: Type-2 diabetes mellitus patients were
selected from a representative sample of the Italian general pop-
ulation aged from 40 to 79 years enrolled in a population based
naturalistic prospective survey. We matched each of them by age
and sex with a non-diabetic subjects. The EuroQoL (EQ-5D), a
self-administered generic questionnaire, completed during the
enrolment visit, was used to evaluate HRQOL. RESULTS: We
analyzed two groups of 157 subjects each (diabetic and non-
diabetic group). The mean age was 63.0 years, 94 (59.9) were
male. Diabetic patients reported more problems than non-
diabetic subjects in the physical sphere, speciﬁcally for mobility
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and usual activities (P = 0.027 and P = 0.006 respectively), while
in self care, pain/discomfort and anxiety/depression dimensions,
there was no statistically signiﬁcant difference between the two
groups. Mean values of the visual analogue scale assessing global
health status indicated by patients with and without type-2 dia-
betes mellitus were 70 (SD, ±16.92) and 72 (SD, ±16.75), respec-
tively (P = 0.395). CONCLUSIONS: This study, comparing
diabetic and non-diabetic patients of the same age and sex,
suggest that the presence of type-2 diabetes mellitus is associated
with higher problems in the physical sphere, speciﬁcally in
domains such as mobility and usual activities, but not on the
overall perception of health status.
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OBJECTIVES: Health-related utility is a numerical measure of
individual satisfaction with health status or health care, and is
routinely used for economic evaluation of new drugs. This study
measured health-related utility in patients with type-2 diabetes
and co-morbidities, such as multiple vascular events, and com-
pared it with utility in non-diabetic patients with similar events.
METHODS: Data were taken from the Health Outcomes Data
Repository, which includes medical histories, biochemistry,
health-related utility (based on the EuroQol-5D), and demo-
graphic data for a large population in the UK. The data used
here (n = 14,775; 8.3% with type-2 diabetes) were from hospi-
tal inpatients and outpatients. RESULTS: The mean health-
related utility score was lower in diabetic patients compared with
non-diabetic patients (0.53 vs. 0.67). The mean utility score for
acute myocardial infarction was 0.58 for those with diabetes
compared with 0.56 for non-diabetic patients. Respective scores
were 0.44 and 0.50 for heart failure; 0.46 and 0.53 for angina;
0.46 and 0.52 for stroke; 0.52 and 0.56 for transient ischaemic
attacks; and 0.44 versus 0.51 for renal failure. The mean utility
scores for peripheral vascular disease were similar in both groups
(0.44 with diabetes and 0.43 without diabetes). The greatest dif-
ference was in eyesight diagnoses, with utility scores of 0.50 for
diabetic versus 0.64 for non-diabetic patients. The mean utility
score was lower (0.58 ± 0.34) for patients with diabetes and no
vascular events compared with patients with neither diabetes nor
a vascular event (0.70 ± 0.31). Utility scores decreased with
increasing number of complications. The difference between dia-
betes and non-diabetes scores decreased with increasing disease
severity, from 0.07 with one event to -0.01 with ≥3 events.
CONCLUSIONS: Type-2 diabetes is associated with decreased
utility, which is affected by the degree of co-morbidity. These
ﬁndings could affect how multiple vascular complications states
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Disease management assessment involves several steps: diagno-
sis, short and long term studies. From the hospital educational
experience conducted in Vichy, hospital and ofﬁce based practi-
tioners developed a coordinated and multidisciplinary therapeu-
tic educational approach, the “Vichy Diabète healthcare
network”. Two assessment steps have been conducted. OBJEC-
TIVES: Initial objective was to analyse the “hospital therapeutic
education program” on diabetic patients knowledge and to iden-
tify ways for improvement. The objective of the second step was
to validate, after a few months, the choices made by the network.
METHODS: Qualitative and quantitative studies were based on
data currently collected, questionnaires submitted to diabetic
patients who followed the hospital program and practitioners
who belong to the network. RESULTS: Initial assessment
showed that the hospital program impact alone is modest. A
total of 67% of the patients considered that diabetes is a severe
disease; 68% estimated that they do their best to treat them-
selves; 60% declared that the treatment is difﬁcult in every day
life, 50% hadn’t changed their behaviour since the diabetes diag-
nostic; 21% didn’t know the potential complications. This
underlined the need to develop the “Vichy Diabète network”.
The second step conﬁrmed these observations; 87.9% of inter-
viewed practitioners estimated that patients could improve their
behaviour. According to them, respectively 57.5% and 66.7%
didn’t know well the targeted glycaemia and HbA1C deﬁnition,
42.4% thought that diabetes isn’t a severe disease. Adherence to
diet and physical activity recommendations is considered very
insufﬁcient. Thus, according to patients and practitioners, the
“Vichy Diabète network” answered to their needs and expecta-
tions. CONCLUSIONS: Assessment approach conducted at dif-
ferent steps is particularly adapted to networks project. It brings
a lot of information to network care givers on strategic choices
and impact on health organisation.
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OBJECTIVES: To assess views of primary care physicians
(PCP’s) in Spain regarding the purposes and impact of inspection
validation of prescriptions (IVP) (in Spain known as “inspector
visa”) prior to dispensing within the NHS, in general and par-
ticularly in type-2 diabetes mellitus (T2DM) drugs, and to what
extent they are in favour of this control mechanism. METHODS:
A telephone survey was conducted during October—November,
2003 of 1471 PCP’s prescribing an oral antidiabetic requiring
IVP, or being familiar with it. Sample sizes per stratum
(Autonomous Region) were calculated with a precision of 10%
and an alpha-error of 0.05. Data was weighted in order to keep
representativeness at a regional and a national level. RESULTS:
A total of 40.6% of the 3618 PCP’s contacted agreed to partic-
ipate in the study and met inclusion criteria. On average, they
prescribe 30.6 drugs requiring IVP per month, and costs of time
invested in tasks related to IVP are estimated around 33€ million
annually in primary care. Twenty percent (20%) of PCP’s
declared that IVP put patients at risk of not receiving the appro-
priate treatment when they need it, and 56.5% believe that IVP
could delay the onset of treatment with T2DM drug. Regarding
T2DM drugs, 18.8% of PCP’s believed that Health Authorities
imposed the IVP requirement to ensure its appropriate utilisa-
